Open·Listed in the source's current feed today
Research on Complex Generics
Food and Drug Administration
Apply at Food and Drug Administration
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Nov 14, 2026
- Amount
- $2,500,000
- Closes
- Dec 14, 2026 (in 30 days)
Similar opportunities open now
- Reissue of RFA-FD-23-001- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)Same funderOpenFood and Drug AdministrationCloses May 2028Up to $900K
- Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)Same funderOpenFood and Drug AdministrationCloses Feb 2028Up to $600K
- Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)OpenNational Institutes of HealthCloses Nov 2027Up to $300K
- Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)OpenNational Institutes of HealthCloses Feb 2028
- Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not AllowedSame funderOpenFood and Drug AdministrationCloses Apr 2027Up to $300K
Classification and identifiers
- Solicitation number
- RFA-FD-27-001
- Assistance listing (CFDA)
- 93.103
Amount
$2,500,000
Who can apply
Only the following applicant is eligible to apply for this single source funding: The University of Maryland
About this opportunity
The purpose of this funding opportunity is to expand access for Americans to high-quality, safe, and effective generic medicines, and help reduce the risk of drug shortages through a more competitive and multi-sourced generic drug market in the U.S., congruent with FDA’s Public Health Pillars.